News & Analysis as of August 27, 2025

Summary Judgment

+ Follow

A repository for the most well-read content on JD Supra at any given time, along with occasional roundups of popular content by specific topic. Also stop by for monthly recaps of hot articles for the previous... more +

Government Pivots to False-Certification Theory in Regeneron Case

Alston & Bird on 8/11/2025

Our Health Care Litigation Team discusses a District of Massachusetts case holding that allows the government to switch liability theories in its False Claims Act lawsuit against Regeneron Pharmaceuticals....more

Lilly v. FDA: Two Stories Collide to Make this GLP-1 Case a Tale of Our Time

Fuerst Ittleman David & Joseph on 1/15/2025

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her Endpoints News story about the case. Lilly’s lawsuit, filed in September 2024 in the Southern...more

3rd Circuit Weighs In On Product-Hopping

WilmerHale on 11/4/2016

On Sept. 28, 2016, in Mylan Pharmaceuticals Inc. v. Warner Chilcott Public Limited Co. (Doryx), the Third Circuit affirmed the lower court’s grant of summary judgment rejecting antitrust claims brought against Warner Chilcott...more

DC District Court Strikes Down 340B Orphan Drug Rule

Foley Hoag LLP on 6/7/2014

On May 23, Judge Contreras of the U.S. District Court for the District of Columbia (DC District Court) ruled that the Health Resources and Services Administration (HRSA) did not have the statutory authority to promulgate its...more

4 Results

View per page

Page: of 1

Today's Popular Updates › Pharmaceutical Industry › Summary Judgment

Government Pivots to False-Certification Theory in Regeneron Case

Lilly v. FDA: Two Stories Collide to Make this GLP-1 Case a Tale of Our Time

3rd Circuit Weighs In On Product-Hopping

DC District Court Strikes Down 340B Orphan Drug Rule

"My best business intelligence, in one easy email…"